JP2022536687A5 - - Google Patents
Info
- Publication number
- JP2022536687A5 JP2022536687A5 JP2021573404A JP2021573404A JP2022536687A5 JP 2022536687 A5 JP2022536687 A5 JP 2022536687A5 JP 2021573404 A JP2021573404 A JP 2021573404A JP 2021573404 A JP2021573404 A JP 2021573404A JP 2022536687 A5 JP2022536687 A5 JP 2022536687A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- migrastat
- patient
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025076158A JP2025131572A (ja) | 2019-06-11 | 2025-05-01 | 腎機能障害を有する患者のファブリー病を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962859904P | 2019-06-11 | 2019-06-11 | |
| US62/859,904 | 2019-06-11 | ||
| PCT/US2020/037174 WO2020252129A1 (en) | 2019-06-11 | 2020-06-11 | Methods of treating fabry disease in patients having renal impairment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076158A Division JP2025131572A (ja) | 2019-06-11 | 2025-05-01 | 腎機能障害を有する患者のファブリー病を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022536687A JP2022536687A (ja) | 2022-08-18 |
| JP2022536687A5 true JP2022536687A5 (https=) | 2023-06-20 |
| JP7677910B2 JP7677910B2 (ja) | 2025-05-15 |
Family
ID=71950725
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573404A Active JP7677910B2 (ja) | 2019-06-11 | 2020-06-11 | 腎機能障害を有する患者のファブリー病を治療する方法 |
| JP2025076158A Pending JP2025131572A (ja) | 2019-06-11 | 2025-05-01 | 腎機能障害を有する患者のファブリー病を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076158A Pending JP2025131572A (ja) | 2019-06-11 | 2025-05-01 | 腎機能障害を有する患者のファブリー病を治療する方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220313670A1 (https=) |
| EP (1) | EP3982962A1 (https=) |
| JP (2) | JP7677910B2 (https=) |
| KR (1) | KR20220019796A (https=) |
| CN (1) | CN114423427A (https=) |
| AR (1) | AR120055A1 (https=) |
| AU (2) | AU2020291002A1 (https=) |
| BR (1) | BR112021024886A2 (https=) |
| CA (1) | CA3141226A1 (https=) |
| CL (1) | CL2021003280A1 (https=) |
| EA (1) | EA202290024A1 (https=) |
| IL (1) | IL288677A (https=) |
| MX (1) | MX2021015352A (https=) |
| PH (1) | PH12021553102A1 (https=) |
| TW (1) | TW202112372A (https=) |
| WO (1) | WO2020252129A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2533050T6 (pl) | 2006-05-16 | 2016-05-31 | Amicus Therapeutics Inc | Możliwości leczenia choroby Fabry'ego |
| EP2946785B1 (en) | 2008-02-12 | 2018-10-24 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| CA3224546C (en) | 2017-05-30 | 2026-02-24 | Amicus Therapeutics, Inc. | Use of migalastat in the treatment of fabry patients |
| KR20200128676A (ko) | 2018-02-06 | 2020-11-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도 |
| US12594268B2 (en) | 2018-08-20 | 2026-04-07 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| KR20220044560A (ko) | 2019-08-07 | 2022-04-08 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| MX2009010557A (es) | 2007-03-30 | 2009-11-19 | Amicus Therapeutics Inc | Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas. |
| MX2009011473A (es) * | 2007-04-26 | 2010-01-18 | Amicus Therapeutics Inc | Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas. |
| EP2946785B1 (en) | 2008-02-12 | 2018-10-24 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| SG10201604757RA (en) * | 2011-03-11 | 2016-08-30 | Amicus Therapeutics Inc | Dosing regimens for the treatment of fabry disease |
| TW202408513A (zh) * | 2016-07-19 | 2024-03-01 | 美商阿米庫斯醫療股份有限公司 | 治療ert初治的和已經歷ert的患者中之法布瑞氏症 |
| WO2018127920A1 (en) * | 2017-01-05 | 2018-07-12 | Protalix Ltd. | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase |
| CA3224546C (en) * | 2017-05-30 | 2026-02-24 | Amicus Therapeutics, Inc. | Use of migalastat in the treatment of fabry patients |
| AR111971A1 (es) * | 2017-05-30 | 2019-09-04 | Amicus Therapeutics Inc | Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal |
| RS65230B1 (sr) * | 2017-05-30 | 2024-03-29 | Amicus Therapeutics Inc | Migalastat za lečenje pacijenata koji boluju od fabrijeve bolesti sa oštećenjem bubrega |
-
2020
- 2020-06-11 MX MX2021015352A patent/MX2021015352A/es unknown
- 2020-06-11 KR KR1020227000878A patent/KR20220019796A/ko active Pending
- 2020-06-11 AR ARP200101648A patent/AR120055A1/es unknown
- 2020-06-11 AU AU2020291002A patent/AU2020291002A1/en not_active Abandoned
- 2020-06-11 JP JP2021573404A patent/JP7677910B2/ja active Active
- 2020-06-11 US US17/618,277 patent/US20220313670A1/en active Pending
- 2020-06-11 WO PCT/US2020/037174 patent/WO2020252129A1/en not_active Ceased
- 2020-06-11 EP EP20751716.0A patent/EP3982962A1/en active Pending
- 2020-06-11 TW TW109119640A patent/TW202112372A/zh unknown
- 2020-06-11 EA EA202290024A patent/EA202290024A1/ru unknown
- 2020-06-11 CN CN202080042938.3A patent/CN114423427A/zh active Pending
- 2020-06-11 PH PH1/2021/553102A patent/PH12021553102A1/en unknown
- 2020-06-11 BR BR112021024886A patent/BR112021024886A2/pt unknown
- 2020-06-11 CA CA3141226A patent/CA3141226A1/en active Pending
-
2021
- 2021-12-05 IL IL288677A patent/IL288677A/en unknown
- 2021-12-09 CL CL2021003280A patent/CL2021003280A1/es unknown
-
2025
- 2025-05-01 JP JP2025076158A patent/JP2025131572A/ja active Pending
-
2026
- 2026-01-29 AU AU2026200618A patent/AU2026200618A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022536687A5 (https=) | ||
| KR101571163B1 (ko) | 멜라토닌 효능제 치료 | |
| JP2505944B2 (ja) | （Ｓ）―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物 | |
| AU2016226006B2 (en) | Method of treatment with tradipitant | |
| JP6837486B2 (ja) | 加齢に関連する認知障害及び神経炎症を予防及び／又は治療する方法 | |
| Lee et al. | A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma | |
| ES2813674T3 (es) | Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b | |
| KR101390144B1 (ko) | 염증성 장질환 치료제 | |
| BR112014023795B1 (pt) | Uso de inibidores de ccr3 | |
| JPH10510241A (ja) | Ｉｉ型糖尿病治療薬剤としてのケトコナゾール、および、その関連物質の使用法 | |
| KR102747348B1 (ko) | 경구 리파마이신 sv 조성물 | |
| CN108012527A (zh) | 苯并咪唑衍生物用于夜间酸突破的用途 | |
| CN118078835A (zh) | 用于夜间尿频的治疗剂 | |
| ES2950453T3 (es) | Compuestos y composiciones farmacéuticas para su uso en el tratamiento de enfermedades asociadas a la retina utilizando inhibidores de la CCR3 | |
| JP6509729B2 (ja) | 慢性腎臓病の進行抑制又は改善剤 | |
| JP2025160480A (ja) | 不眠症を治療するためのレンボレキサントの使用 | |
| CN112533675A (zh) | 通过递送抗OSMRβ抗体治疗皮肤疾病或病症 | |
| KR102512518B1 (ko) | 페마피브레이트를 함유하는 의약 | |
| BRPI0906158B1 (pt) | composição farmacêutica de liberação modificada compreendendo doxofilina e processo para a preparação de composição | |
| JPH0352816A (ja) | 腎炎の治療剤 | |
| TW202408522A (zh) | 一種稠環嘧啶類化合物的用途 | |
| JP4384435B2 (ja) | くしゃみ抑制組成物 | |
| JP2812998B2 (ja) | 胃炎治療剤 | |
| CN115038446A (zh) | 马赛替尼治疗嗜酸性粒细胞性哮喘的用途 | |
| WO2016006621A1 (ja) | Ｐｇｄ２拮抗剤を含有するアレルギー性疾患に伴う症状の治療用医薬 |